Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGOT-EN1/FANDANGO first-line chemotherapy with nintedanib vs placebo in advanced or recurrent endometrial cancer
2016-000193-38Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometrial cancer (EC) comparing Nintedanib + first-line combination chemotherapy with Placebo + first-line combination chemotherapy (2 arms). Started Apr 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2016-000193-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000193-38.